4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9 Tsarkake>98.5% (HPLC) Lenvatinib Mesylate Intermediate Factory
Ruifu Chemical Supply Lenvatinib Mesylate Matsakaici Tare da Babban Tsafta
Lenvatinib Mesylate CAS 857890-39-2
4-Chloro-7-Methoxyquinoline-6-Carboxamide CAS 417721-36-9
Desquinolinyl Lenvatinib;1- (2-Chloro-4-Hydroxyphenyl) -3-Cyclopropylurea CAS 796848-79-8
Methyl 7-Methoxy-4-Oxo-1,4-Dihydroquinoline-6-Carboxylate CAS 205448-65-3
Methyl 4-Amino-2-Methoxybenzoate CAS 27492-84-8
5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dion CAS 15568-85-1
4-Amino-3-Chlorophenol CAS 17609-80-2
4-Amino-3-Chlorophenol Hydrochloride CAS 52671-64-4
Methyl 4-Chloro-7-Methoxyquinoline-6-Carboxylate CAS 205448-66-4
Sunan Sinadari | 4-Chloro-7-Methoxyquinoline-6-Carboxamide |
Makamantu | 4-Chloro-7-Methoxy-6-Quinolinecarboxamide;Lenvatinib rashin tsarki 12;Lenvatinib Rashin Tsabtace B;Lenvatinib rashin tsabta LFS-B |
Lambar CAS | 417721-36-9 |
Lambar CAT | Saukewa: RF-PI1971 |
Matsayin Hannun jari | A cikin Hannun jari, Ƙarfin Samar da 50MT/Shekara |
Tsarin kwayoyin halitta | Saukewa: C11H9ClN2O2 |
Nauyin Kwayoyin Halitta | 236.65 |
Matsayin narkewa | > 205 ℃ (Dec.) |
Yawan yawa | 1.380± 0.060 g/cm3 |
Alamar | Ruifu Chemical |
Abu | Ƙayyadaddun bayanai |
Bayyanar | Kashe-Fara Zuwa Hasken Foda na Yellow |
Tsarkake / Hanyar Bincike | 98.5% (HPLC) |
Asara akan bushewa | <0.50% |
Ragowa akan Ignition | <0.50% |
Jimlar ƙazanta | <1.50% |
Abubuwan da aka bayar na Proton NMR Spectrum | Yayi daidai da Tsarin |
Matsayin Gwaji | Matsayin Kasuwanci |
Amfani | Matsakaicin Lenvatinib Mesylate (CAS: 857890-39-2) |
Kunshin: Bottle, Aluminum tsare jakar, 25kg / kwali Drum, ko bisa ga abokin ciniki ta bukata
Yanayin Ajiya:Ajiye a cikin kwantena da aka rufe a wuri mai sanyi da bushe;Kare daga haske da danshi
4-Chloro-7-Methoxyquinoline-6-Carboxamide (CAS: 417721-36-9) yawanci ana amfani dashi azaman tsaka-tsakin Lenvatinib Mesylate (CAS: 857890-39-2).Eisai Inc ya haɓaka, lenvatinib mesylate shine mai hanawa na endothelial endothelial growth factor (VEGF) mai hanawa wanda ke da aiki akan VEGF subtypes 1, 2, da 3 kuma FDA ta amince da ita a cikin 2015 don maganin bambance-bambancen ciwon daji na thyroid wanda shine ko dai a gida. mai-maitawa, metastatic, ko ci gaba kuma bai amsa maganin iodine na rediyoaktif ba.A cikin Mayu 2016, FDA ta amince da miyagun ƙwayoyi a matsayin haɗin haɗin gwiwa tare da everolimus don maganin ciwon daji na ƙwayar ƙwayar ƙwayar ƙwayar cuta.Saboda VEGF (da masu karɓar haɓakar haɓakar fibroblast, wanda aka sani da FGFRs) ana tsammanin za su taka rawa a cikin hanyoyin sigina na zuciya, VEGF2R da hana FGFR sune hanyoyin da ke bayan tasirin sakamako na farko na lenvatinib mesylate, wanda shine hauhawar jini.